Parkinson's is a chronic progressive movement disorder characterized by shaking and difficulties with walking, movement, and coordination. The causes of PD are yet unknown, however, several risk factors have been identified, among which are alpha-synucleinand iron overload in the brain.Alpha-synucleinprotein is increased in PD and its toxic form contributes to progressive neurodegeneration of nerve cells that produce dopamine, a chemical that helps regulate movement and muscle coordination. Iron accumulation in these neurons can also contribute to neurodegeneration in PD, because increased intracellular iron is associated with oxidative stress and neuro-inflammation, both of which, in turn, perpetuate the disease.
Entia'sErgoD2 technology aims to slow PD progression by stabilizing iron levels, reducing inflammation, and boosting the internal antioxidant system. At the core of this technology are L-ErgothioneineandErgocalciferol, which, in previous clinical studies conducted byEntiain diabetes and chronic kidney disease, have been shown to stimulate iron export from the cell. These findings are now being applied to PD as a way to reduce the iron burden inside the degenerating dopamine-producing cells. The resulting reduction in intracellular iron levels is hypothesized to mitigate the associated inflammation and oxidative stress in the PD brain, thereby slowing degeneration of nerve cells. This systems-level approach -- designed byEntiaBiosciences -- will also be applied in future clinical studies, in which ErgoD2 will be evaluated for its impact on various biological indicators of health and disease.
"We are grateful and excited to be working with
ErgoD2 is a proprietary pharmaceutical grade organic compound from whole food that contains the micro-nutrients L-Ergothioneine, an amino acid with a dedicated transporter (SLC22A4), andErgocalciferol(vitamin D2).These nutrients are naturally enhanced and concentrated to therapeutic levels usingEntia'spatented technology.
Entiais an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology andNutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.www.entiabio.com.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identifiedin the filings byEntiaBiosciences with the
For more information, please contact:
Chief Operating Officer
Sherwood, OR 97140